You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Software for Determining Proteoform Heterogeneity and Protein Expression Fidelity

    SBC: GENNEXT TECHNOLOGIES, INC.            Topic: 400

    The importance of large protein drugsbiopharmaceuticalsand their generic counterpartsknown as biosimilarshas created a need for improved analytics to facilitate biopharmaceutical research and to combat adverse drug reactionsThe recombinant protein expression process is inherently prone to low level errors resulting in sequence variants caused by amino acid misincorporationwhich are observed in bot ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. Stem Cells for Treating Acute Stroke

    SBC: SANERON CCEL THERAPEUTICS, INC.            Topic: 999

    ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Stimuli Responsive Topical Gels for Mechanically Assisted Wound Debridement

    SBC: LYNNTECH INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Debridement of dead, damaged and/or infected tissue from thermal burn wounds and a certain subset of ischemic and necrotic diabetic foot wounds is a commonly utilized wound preparation modality before the application of fillers, dressings or grafts. The existing wound debridement techniques have serious issues such as invasiveness and impreciseness, painful ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing

    SBC: DYNAMIC ENTROPY TECHNOLOGY, LLC            Topic: NIDDK

    Abstract Diabetic ulcers or pressure ulcers are common for patients with diabetesspinal cord injuriesetcWithout proper managementsuch wounds often lead to infections such as osteomyelitis or sepsisresulting in high mortality and morbidityIn addition to bacterial infectiondiabetic patients are also more susceptible to cutaneous fungal infectionsAdvanced wound dressings and advanced wound therapies ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Synchronous Valveless Pulsatile Support Device for the Failing Heart

    SBC: WINDMILL CARDIOVASCULAR            Topic: NHLBI

    DESCRIPTION (provided by applicant): Heart failure (HF) is a major health problem in the US and worldwide. Over 100,000 people in the US are diagnosed with end stage HF annually. Heart transplantation is performed in only 2% of these cases due to lack of available donor hearts. Mechanical left ventricular assist devices (LVADs, a type of artificial heart) can allow patients with severe HF to live ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Targeted Polymeric Combination Delivery for Treatment of Ovarian Cancer

    SBC: THERATARGET, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): This Phase I proposal details the rationale and the research plan for the synthesis and characterization of a polymeric delivery system that will deliver two anticancer drugs with diverse mechanisms of action simultaneously into ovarian cancer cells. The delivery system will be composed of N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer as the backbone. It i ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Targeted Polymer Micelles for Treatment of Metastatic Melanoma

    SBC: INTEZYNE TECHNOLOGIES, INC.            Topic: NCI

    DESCRIPTION (provided by applicant): According to the American Cancer Society, half of all men and one-third of all women in the United States will develop cancer in their lifetime. While chemotherapy has dramatically improved the survival rate of cancer patients, it comes at the cost of severe toxicities and in some cases poor response rates. In order to address these shortcomings, equal investme ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Targeting endothelial arginase to treat diabetes-associated vascular dysfunction

    SBC: ARGINETIX, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): The product that will result from this STTR is ABH (2(S)-amino-6-boronohexanoic acid), a potent small molecule inhibitor of the enzyme arginase, for treating vascular complications of diabetes. There are 20.8 million Americans with diabetes. More than 65% of these people will die from heart disease or stroke. Men with diabetes are twice as likely, and women wi ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    Glioblastoma (GBM) is the most lethal form of adult brain cancers with a median survival of andlt;15 months despite aggressive standard chemoradiation. GBM are formed by GBM stem-like cells (GSCs) - a major contributor to tumor recurrence and a natural focus for therapeutic development. There are two main reasons responsible for treatment failure: 1) high intra- and inter-tumor cellular and molecu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Targeting lipid rafts for treatment of asthma

    SBC: RAFT PHARMACEUTICALS LLC            Topic: NIAID

    PROJECT SUMMARY Asthma, characterized by airways obstruction with symptoms of wheezing, shortness of breath, chest tightness and consequently cough, remains a significant health problem. While advances in bronchodilator, corticosteroid and Th2-targeting therapy allow for well-controlled asthma in a large population of patients, subjects with severe, corticosteroid resistant asthma require frequent ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government